Pharma Diagnostics - April 3, 2017
Swedish prostate cancer test to be introduced in Europe
The new Stockholm3 test for prostate cancer diagnosis, gets assistance from EIT Health for a faster introduction in Europe. In a first step the test will be clinically validated in Germany, the Netherlands and Belgium. The Stockholm3 test was developed by researchers at Karolinska Institutet. EIT Health, supported by the EU body European Innovation and […]
Uncategorized - November 21, 2016
Improved prediction of prostate cancer survival
Results of the Prostate Cancer DREAM Challenge published in the clinical oncology journal Lancet Oncology demonstrate the benefits of sharing clinical trial data. The winning prediction model was developed by a team headed by FIMM Group Leader Tero Aittokallio. Overall, this collaborative scientific effort led to novel insights and improvements in cancer treatment and management. In 2015, professor Aittokallio’s team excelled in Sage […]
Biotech Business - May 3, 2015
Active to Lay Off 47 Workers
A month after Swedish company Active Biotech AB reported that its Phase III trial of 10TASQ10 in castration-resistant prostate cancer reached its primary endpoint but did not increase peoples’ overall survival, the company announced plans to lay off 47 people. Active Biotech and French company Ipsen collaborated on the study of 10TASQ10 (tasquinimod). While the drug reduced the risk of radiographic cancer […]
Collaboration - April 1, 2015
Medicon Valley, U.S. Cluster Partner
The Medicon Valley group, which includes Copenhagen, the capital and Zealand regions of Denmark and the Skåne region in Sweden, has entered a partnership with the Massachusetts (U.S.) Life Science Cluster (MLSC) to develop new drugs and healthcare technology. Among the projects is an effort to develop a new drug for prostate cancer, which is […]
Drug Development Pharma - February 25, 2015
Bavarian Nordic to Present Findings at Symposium
Bavarian Nordic plans to present updated overall survival data from an NCI sponsored combination study of its active prostate cancer immunotherapy candidate PROSTVAC and ipilimumab, an immune checkpoint inhibitor, at the Genitourinary Cancers Symposium in Orlando, FL on Feb. 26. Approximately 20 perecent of men with advanced prostate cancer treated with PROSTVAC and Ipilimumab were alive 80 months after initiating […]
Uncategorized - April 17, 2014
New findings on prostate cancer treatment
Rigshospitalet in Denmark has developed a new type of treatment using alpha rays in liquid form which has fewer side-effects and means better chances of survival for patients with prostate cancer. The substance is injected into the arteries through a venflon catheter and then it flows around with the blood and becomes trapped in the […]
